secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2022-05-03T23:59:59+00:00
Accession:  0001127537-22-000015
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q1 revenue $10.8M (+17% YoY); net loss $15.8M; reaffirms FY 2022 guidance
--------------------------------------------------------------------------------

- Worldwide revenue $10.8M, up 17% YoY (20% constant currency); US revenue $6.0M (+40%).
- Net loss $15.8M ($0.43/share) vs. $12.5M loss ($0.35/share) in Q1 2021.
- Gross margin improved to 75% from 72% YoY, driven by production efficiencies.
- Added 16 new US Zephyr Valve treatment centers; total 230 centers.
- FY 2022 outlook unchanged: revenue $55-60M; operating expenses $100-105M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753722000015/0001127537-22-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753722000015/lung-20220503.htm
  HTML page:      https://secwatch.observer/filing/0001127537-22-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer